Overview: Anti-Neuromyelitis Optica Panel
Introduction: The Anti-Neuromyelitis Optica Panel is a diagnostic tool designed to screen for neuromyelitis optica using serum or CSF samples. In India, NMO spectrum disorders (NMOSD) are increasingly recognized (prevalence ~1-5 per 100,000), with AQP4-IgG positivity in 60-80 percent and MOG-IgG in seronegative cases. Presents with optic neuritis, transverse myelitis, intractable hiccups/nausea, and relapsing course leading to disability. High morbidity from underdiagnosis in neurology clinics, limited CSF testing, overlap with MS/TB, and delayed immunosuppressive therapy causing blindness or paralysis. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for early diagnosis and differentiation from MS. This diagnostic falls under neurological disorder screening and targets patients with suspected NMOSD, addressing accurate detection to guide plasma exchange or rituximab. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing disability. Its serum/CSF-based approach ensures reliable detection.
Other Names: NMO Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: AQP4 discovery in 2004; in India, prominence with NMOSD registries.
Purpose: The test screens for 2 parameters including aquaporin-4 antibody to guide NMOSD diagnosis, differentiate from MS, inform therapy.
Test Parameters: 1. Aquaporin-4 Antibody, 2. MOG Antibody.
Pretest Condition: No fasting required; patients should report optic neuritis, myelitis, or intractable hiccups.
Specimen: 3 mL serum in 1 SST or CSF in sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on vision loss, weakness, sensory symptoms, relapses, or family autoimmune history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated NMOSD including disability, benefits of early detection, and minimal discomfort from blood/CSF draw.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive AQP4/MOG indicates NMOSD, necessitating specialist input. Negative may require follow-up if suspicion persists.
Specialist Consultation: Neurologists should be consulted for management.
Additional Supporting Tests: MRI spine/brain for confirmation.
Test Limitations: May miss seronegative cases; comprehensive approach required.
References: Indian Journal of Neurology 2024, NMOSD Studies India 2023.
